nAMD and RVO: Understanding the Impact on Patient Lives and the Need for Timely Diagnosis and Referral

nAMD and RVO: Understanding the Impact on Patient Lives and the Need for Timely Diagnosis and Referral

nAMD and RVO: Understanding the Impact on Patient Lives and the Need for Timely Diagnosis and Referral

The number of individuals diagnosed with AMD and RVO increases daily. Make sure you’re doing everything to prevent vision loss in these patients.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Approximately 2 million individuals in the United States are living with age-related macular degeneration (AMD), and another 1.6 million are living with retinal vein occlusion (RVO). These numbers are increasing daily due to an aging population and prevalence of risk factors. There have been many advances in treatment, but what else can you be doing to prevent vision loss in your patients?

    In this activity, Dr. Emily Chew speaks with Drs. Neil Bressler, Joseph Coney, and Steven Ferrucci to examine the evidence around early diagnosis, referral, and treatment of AMD and RVO and the impact of these diseases on patients’ lives.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Emily Chew, MD
    Director, Division of Epidemiology and Clinical Applications
    Deputy Clinical Director
    National Eye Institute
    Bethesda, MD 

    Dr. Chew has no relevant relationship reported.

    Neil M. Bressler, MD
    James P. Gills Professor of Ophthalmology
    The Johns Hopkins Hospital
    Baltimore, MD 

    Dr. Bressler has no relevant relationship reported.

    Joseph M. Coney, MD
    Retina Associates of Cleveland
    Case Western Reserve University School of Medicine
    University Hospitals of Cleveland
    Cleveland, OH 

    Consulting Fees: Alcon Laboratories, Alimera, Allergan, Genentech, Novartis, Regeneron Pharmaceuticals
    Contracted Research: Aerpio, Alcon Laboratories, Alimera, Allergan, Apellis, Genentech, Hoffman-LaRoche, Novartis, Tyrogenex
    Ownership Interest: Regeneron Pharmaceuticals

    Steven Ferrucci, OD, FAAO
    Chief, Optometry
    Sepulveda VA
    North Hills, CA 

    Consulting Fees: Genentech, Maculogix, Inc., Regeneron Pharmaceuticals, Visible Genomics
    Commercial Interest Speakers Bureau: Genentech, Maculogix, Inc., Optovue, Regeneron Pharmaceuticals

    Reviewers/Content Planners/Authors:

    • Rob Braun has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP, has nothing to disclose.
    • Mindy Nash, OD, has nothing to disclose.
    • Robert Schneider, MSW, has nothing to disclose.
    • Stephanie Wenick has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss how timely referral and early diagnosis can minimize and even prevent the risk of vision-threatening complications from nAMD and RVO
    • Recognize strategies for team-based care to support aging patients at risk for or with AMD or RVO
  • Target Audience

    This activity is designed to meet the educational needs of optometrists, general ophthalmologists, and retina specialists.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Learning Collaborative (GLC) and the National Eye Institute of the National Institutes of Health, of the U.S. Department of Health and Human Services. GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

    ReachMD Healthcare Image

    This activity is provided in partnership with the National Eye Institute, of the National Institutes of Health, of the US Department of Health and Human Services. The National Eye Health Education Program of the NEI is acknowledged for its important contributions to this initiative.

  • Commercial Support

    This activity is supported by an independent educational grant from Regeneron Pharmaceuticals Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free